IMUX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunic Inc (IMUX) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there is potential upside from its clinical pipeline, the company's weak financial performance, lack of significant trading signals, and mixed technical indicators suggest that it may be prudent to wait for clearer positive developments or a more favorable entry point.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is below 0 and negatively contracting, indicating weak momentum. RSI is in the neutral zone at 70.386. Key resistance levels are at 1.275 and 1.341, with support at 1.061 and 0.995. The stock's recent price action suggests moderate upward movement but lacks strong conviction.
The company is advancing its phase 3 clinical trial for IMU-838, which has potential as a first-in-class therapy for multiple sclerosis. Analysts see substantial upside if the trial confirms efficacy and safety. The company is also developing earlier-stage programs targeting neurodegenerative and autoimmune diseases.
The company warns of risks related to macroeconomic trends and uncertainties in clinical trials. Financial performance is weak, with declining net income (-23.34% YoY) and EPS (-60.00% YoY). Additionally, there are no significant hedge fund or insider trading trends, and no recent congress trading data.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$19.3 million (-23.34% YoY), and a significant EPS decline of -60.00% YoY. Gross margin remains at 0%. The financials indicate poor profitability and no revenue generation.
Guggenheim initiated coverage with a Buy rating and a $7 price target, citing potential upside from the phase 3 trial of vidofludimus calcium. However, H.C. Wainwright recently lowered its price target from $8 to $5 while maintaining a Buy rating, reflecting tempered expectations.
